

# Eye Allergy Therapeutics Market - Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

LONDON, GREATER LONDON, UNITED KINGDOM, August 20, 2025

/EINPresswire.com/ -- What Is The Projected Market Size & Growth Rate Of The [Eye Allergy Therapeutics Market?](#)

In recent times, the market for eye allergy therapeutics has experienced substantial growth. The market size is

predicted to expand from \$3.04 billion in 2024 to \$3.23 billion in 2025, marking a compound annual growth rate (CAGR) of 6.4%. The accelerated growth during the past era is credited to factors such as the heightened incidence of allergic conjunctivitis, better public understanding of eye allergies, an increase in urban pollution levels, more access to sophisticated treatments, and improvements in healthcare infrastructure.



Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors”

*The Business Research Company*

In the coming years, the eye allergy therapeutics market is anticipated to experience robust growth, reaching a market size of \$4.10 billion in 2029, progressively growing at a 6.1% compound annual growth rate (CAGR). This predicted growth within the forecast period can be linked to factors such as the expanding elderly population, increased usage of biologics, rising investments in ophthalmic research, enhanced awareness of eye allergy symptoms, and progress in drug delivery technologies.

Significant trends expected during the forecast period involve progress in personalized medicine, innovation in sustained-release formulations, incorporation of digital diagnostics, advancements in biologic therapies, and novel developments in non-invasive treatment methods.

Download a free sample of the eye allergy therapeutics market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=25765&type=smp>

What Are The Factors Driving The Eye Allergy Therapeutics Market?



The Business  
Research Company

The Business Research Company

The [eye allergy therapeutics market growth](#) is anticipated to experience growth due to the escalating occurrence of eye allergies. Eye allergies are immune system responses that result in inflammation and irritation of the eyes triggered by allergens. The frequency of eye allergies is on the rise due to increased environmental pollution, which exposes individuals to a greater number of airborne allergens and subsequently, ignites more allergic reactions. Eye allergy treatments are designed to manage eye allergies by reducing inflammation, easing redness and itching, and hindering allergic responses to provide efficient relief of symptoms. As an example, in May 2025, the National Library of Medicine, a biomedical library based in the US, revealed that ocular allergy (OA) affected 49.3% (n=207) of the studied cases, with seasonal allergic conjunctivitis (SAC) making up 90.3%, largely among 14-year-olds (23.4%) and females (58.8%). Therefore, the growing prevalence of eye allergies is fueling the expansion of the eye allergy therapeutics market.

#### Which Companies Are Currently Leading In The Eye Allergy Therapeutics Market?

Major players in the Eye Allergy Therapeutics Global Market Report 2025 include:

- Pfizer Inc.
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Limited
- Regeneron Pharmaceuticals Inc.
- Alcon Inc.

#### What Are The Top Trends In The Eye Allergy Therapeutics Industry?

Big players in the eye allergy treatment sector are directing their efforts towards creating novel products such as anti-itch therapy for eye allergies. These specialized eye treatments help quickly alleviate symptoms, enhance patient satisfaction, and broaden customer availability due to their over-the-counter accessibility. The term 'eye allergy itch relief therapeutics' is used to describe remedies specifically designed to soothe itching resulting from allergic reactions in the eyes. For example, in August 2024, the pharmaceutical company based in India, Glenmark Pharmaceuticals Limited, introduced Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC), with the goal of alleviating symptoms of eye allergies. This prescription, suitable for use twice daily, offers swift and prolonged respite from symptoms of allergic conjunctivitis, including itching, redness, and watery eyes. The OTC option aligns with the increasing appetite for self-care remedies and promotes larger customer engagement in the eye care section.

#### Comparative Analysis Of Leading Eye Allergy Therapeutics Market Segments

The eye allergy therapeutics market covered in this report is segmented –

- 1) By Drug Class: Antihistamines, Mast Cell Stabilizers, Dual-Action Agents, Corticosteroids,

Decongestants, Immunotherapy, Other Drug Classes

2) By Allergy Type: Seasonal Allergic Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC), Giant Papillary Conjunctivitis

3) By Route of Administration: Topical, Oral, Injectable, Ocular, Systemic

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels

5) By End User: Hospitals, Clinics, Homecare Settings, Pharmacies, Research Institutions

Subsegments:

1) By Antihistamines: Olopatadine, Ketotifen, Emedastine, Levocabastine, Bepotastine

2) By Mast Cell Stabilizers: Cromolyn Sodium, Nedocromil, Lodoxamide, Pemirolast

3) By Dual-action Agents: Olopatadine, Ketotifen Fumarate, Azelastine, Alcaftadine

4) By Corticosteroids: Loteprednol Etabonate, Prednisolone Acetate, Dexamethasone, Fluorometholone

5) By Decongestants: Naphazoline, Tetrahydrozoline, Oxymetazoline, Phenylephrine

6) By Immunotherapy: Subcutaneous Immunotherapy, Sublingual Immunotherapy, Allergen-specific Desensitization Drops

7) By Other Drug Classes: Nonsteroidal Anti-inflammatory Drugs, Biologics

View the full eye allergy therapeutics market report:

<https://www.thebusinessresearchcompany.com/report/eye-allergy-therapeutics-global-market-report>

Which Regions Are Dominating The Eye Allergy Therapeutics Market Landscape?

In 2024, North America led the global market for eye allergy therapeutics. The anticipated growth trends of this region are detailed in the Eye Allergy Therapeutics Global Market Report 2025. The comprehensive report also includes other regions namely Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Eye Allergy Therapeutics Market 2025, By [The Business Research Company](#)

Anemia And Other Blood Disorder Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report>

Ocular Inflammation Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/ocular-inflammation-treatment-global-market-report>

Dry Eye Medication Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/dry-eye-medication-market>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - [www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com)

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/841407928>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.